C&G Editor in Chief, Erin Harris

  1. In Vivo Gene Editing Is Moving From Promise To Proof 6/15/2026

    CGT is shifting from technical promise to clinical execution as in vivo approaches reach an inflection point where delivery, durability, specificity, and manufacturability will determine whether the field can turn breakthrough science into safe, scalable, repeatable therapies.

  2. Driving Gene Therapy Beyond Rare Disease Will Define The Next Era Of CGT 6/2/2026

    Gene therapy’s next test is not proving it works, but proving it can scale.

  3. CGT Manufacturing Shifts From Capacity To Strategy 5/21/2026

    As manufacturing overcapacity reshapes the CGT landscape, success now depends less on access to capacity and more on strategic alignment across development, regulatory readiness, and long-term commercialization.

  4. Dr. Peter Marks On Why Gene Therapy May Need A New Regulatory Playbook 5/13/2026

    At the 2026 @Philly Cell and Gene Therapy Annual Conference, Dr. Peter Marks highlighted how gene therapy science is surging ahead and called for smarter regulatory evolution to unlock treatments for thousands of rare disease patients.

  5. Regeneron Advances In Vivo Gene Therapy For Hearing Loss 5/1/2026

    Regeneron’s Otarmeni marks a major CGT milestone, showing that in vivo gene therapy can restore hearing in OTOF-related deafness while expanding the field’s clinical and delivery possibilities.

  6. Sana, Mayo Clinic Advance A New Model For Cell Therapy Delivery In T1D 4/27/2026

    Sana Biotechnology and Mayo Clinic are partnering to standardize delivery of a one-time hypoimmune cell therapy, aiming to scale access and redefine care for type 1 diabetes.

  7. Reprogramming T-Cell Access To Solid Tumors Through Improved Trafficking And Entry 4/17/2026

    Here's why trafficking and entry remain key barriers to CAR T success in solid tumors.

  8. Target Selection Drives The Future Of CAR T Therapy In Solid Tumors 4/13/2026

    Target selection is the defining challenge in CAR T therapy for solid tumors, shaping safety, efficacy, and the field’s path forward.

  9. Mitigating Challenges In Solid Tumor Delivery 4/3/2026

    CAR T-cell therapy is advancing in solid tumors by improving target selection, trafficking, tumor-microenvironment resistance, and long-term function, but major biological barriers still require combined solutions.

  10. Ensuring Quality Of CGT Materials 3/24/2026

    Here's why strong material selection, risk-based controls, and early analytics are critical for successful CGT development.